Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
EJNMMI Physics|March 31, 2021
Tissue dose estimation after extravasation of 177Lu-DOTATATEPerrine Tylski, Géraldine Pina-Jomir, Claire Bournaud-Salinas, et al.Annales D'Endocrinologie|August 30, 2014
New-generation thyroglobulin assay: performance and implications for follow-up of differentiated thyroid carcinomaChristelle Roger, Karim Chikh, Véronique Raverot, et al.Neurosurgery|August 9, 2019
Minimal-Access Endoscopic Endonasal Management of Dysthyroid Optic Neuropathy: The Dysthone StudyGilles Zah-Bi, Juliette Abeillon-du Payrat, Anne Laure Vie, et al.Clinical Nuclear Medicine|March 21, 2017
FDOPA Patterns in Adrenal Glands: A Pictorial EssayAurélie Moreau, Anne Laure Giraudet, David Kryza, et al.European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
Predictive factors of outcome in poorly differentiated thyroid carcinomasChristelle de la Fouchardière, Myriam Decaussin-Petrucci, Julien Berthiller, et al.European Thyroid Journal|December 27, 2021
Long-Term Outcome of Lobectomy for Thyroid CancerMatthieu Bosset, Maxime Bonjour, Solène Castellnou, et al.Targeted Oncology|August 20, 2015
Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective StudyChristelle de la Fouchardiere, Nadia Oussaid, Olfa Derbel, et al.European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.The Journal of Clinical Endocrinology and Metabolism|July 26, 2013
One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paragangliomaSégolène Hescot, Sophie Leboulleux, Laurence Amar, et al.Pageof 1